← back to search

Michele Stanislaw Milella

University of Verona · IT
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, and Cancer Genomics and Diagnostics.
h-index
32
citations
6,839
works
939
NIH funding
primary concept
email

Recent publications

Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization
The Journal of Pathology 2025cited by 13position: middledoi
Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC
JTO Clinical and Research Reports 2025cited by 3position: middledoi
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration
Journal of Clinical Medicine 2024cited by 2position: middledoi
Safety of direct-acting antivirals for Hepatitis C infection and direct oral anticoagulants co-administration: an Italian multicentric study
Digestive and Liver Disease 2024cited by 0position: middledoi
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
Leukemia 2019cited by 42position: middledoi
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
The Lancet Oncology 2018cited by 573position: middledoi
The present profile of chronic hepatitis B virus infection highlights future challenges
Digestive and Liver Disease 2018cited by 20position: middledoi
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
˜The œLancet. Gastroenterology & hepatology 2017cited by 19position: middledoi
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents.
Journal of Clinical Oncology 2017cited by 0position: middledoi
Cocaine cue–induced dopamine release in the human prefrontal cortex
Journal of Psychiatry and Neuroscience 2016cited by 56position: firstdoi
Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer
Critical Reviews in Oncology/Hematology 2016cited by 10position: middledoi
Single-Agent or Doublets As Second-Line Chemotherapy After Folfirinox in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Annals of Oncology 2014cited by 1position: middledoi
Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
Journal of Clinical Oncology 2014cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniele Santini · Azienda Ospedaliera Sant'Andrea4 papers (2014–2017)Giuseppe Procopio · Fondazione IRCCS Istituto Nazionale dei Tumori2 papers (2014–2017)Ugo De Giorgi · University of Salento2 papers (2014–2017)Roberto Sabbatini · Ospedali Riuniti Umberto I2 papers (2014–2017)Matteo Santoni · Istituti di Ricovero e Cura a Carattere Scientifico2 papers (2014–2014)Stefano Cascinu · Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele2 papers (2014–2014)Giuseppe Di Lorenzo · University of Alabama at Birmingham1 papers (2014–2014)Chawki Benkelfat · Montreal Neurological Institute and Hospital1 papers (2016–2016)Paul Gravel · Yale University1 papers (2016–2016)Marco Leyton · Montreal Neurological Institute and Hospital1 papers (2016–2016)Alessio Aghemo · Istituti di Ricovero e Cura a Carattere Scientifico1 papers (2024–2024)Sergio Bracarda · Istituto Oncologico Veneto1 papers (2017–2017) · 1 papers (2025–2025) · 1 papers (2025–2025)Francesco Massari · University Psychiatric Hospital1 papers (2014–2014)Maddalena Barba · University of Birmingham1 papers (2016–2016)Roberto Iacovelli · Cancer Research UK1 papers (2014–2014) · 1 papers (2024–2024)Marcello Dallio · AbbVie (United States)1 papers (2024–2024)Rodolfo Passalacqua · Istituti Ospitalieri di Cremona1 papers (2017–2017)